Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivonescimab - Akeso Biopharma/Summit Therapeutics

Next Previous
X
Search
Drug Profile

Ivonescimab - Akeso Biopharma/Summit Therapeutics

Alternative Names: AK-112; Evoximab; PD-1/VEGF bi-specific antibody - Akeso Biopharma; SMT-112

Latest Information Update: 14 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Developer Akeso Biopharma; Summit Therapeutics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Squamous cell cancer
  • Phase II Colorectal cancer; Gynaecological cancer; Liver cancer; Triple negative breast cancer
  • Phase I/II Ovarian cancer; Solid tumours
  • Phase I Small cell lung cancer

Most Recent Events

  • 10 Jan 2025 Akeso plans a phase III trial for Triple-negative breast cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV, Infusion), in January 2025 (NCT06767527)
  • 13 Nov 2024 Akeso plans phase-II trial for Ovarian cancer, Fallopian tube cancer and Primary peritoneal cancer (Combination therapy) in December 2024 (IV) (NCT06686030)
  • 30 Oct 2024 Phase-III clinical trials in Squamous cell cancer (First-line therapy, Combination therapy, Metastatic disease, Recurrent) in China (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top